ANI PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Description as filed by funds: Election of Directors: Antonio R. Pera

ANI PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Antonio R. Pera”): 16,451,771 for, 447,404 against, per its Form 8-K filed May 23, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, (i) the eight directors were elected, (ii) the appointment of the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified, (iii) the compensation of the Company's named executive officers, on an advisory basis, was app…”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 6,501,186 for, 48 against, 1,630 abstained.

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

Description as filed by funds: Election of Directors: Jeanne A. Thoma

ANI PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jeanne A. Thoma”): 16,487,783 for, 411,401 against, per its Form 8-K filed May 23, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, (i) the eight directors were elected, (ii) the appointment of the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified, (iii) the compensation of the Company's named executive officers, on an advisory basis, was app…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 6,501,186 for, 48 against, 1,630 abstained.

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

Description as filed by funds: Election of Directors: Matthew J. Leonard, R.Ph.

ANI PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Matthew J. Leonard, R.Ph.”): 16,286,549 for, 615,181 against, per its Form 8-K filed May 23, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, (i) the eight directors were elected, (ii) the appointment of the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified, (iii) the compensation of the Company's named executive officers, on an advisory basis, was app…”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 6,168,458 for, 332,776 against, 1,630 abstained.

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

Description as filed by funds: Election of Directors: Muthusamy Shanmugam

ANI PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Muthusamy Shanmugam”): 16,785,294 for, 116,444 against, per its Form 8-K filed May 23, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, (i) the eight directors were elected, (ii) the appointment of the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified, (iii) the compensation of the Company's named executive officers, on an advisory basis, was app…”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 6,501,186 for, 48 against, 1,630 abstained.

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

Description as filed by funds: Election of Directors: Nikhil Lalwani

ANI PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Nikhil Lalwani”): 16,838,898 for, 68,125 against, per its Form 8-K filed May 23, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, (i) the eight directors were elected, (ii) the appointment of the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified, (iii) the compensation of the Company's named executive officers, on an advisory basis, was app…”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 6,501,186 for, 48 against, 1,630 abstained.

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

Description as filed by funds: Election of Directors: Patrick D. Walsh

ANI PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Patrick D. Walsh”): 16,477,655 for, 424,150 against, per its Form 8-K filed May 23, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, (i) the eight directors were elected, (ii) the appointment of the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified, (iii) the compensation of the Company's named executive officers, on an advisory basis, was app…”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 6,482,013 for, 19,221 against, 1,630 abstained.

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

Description as filed by funds: Election of Directors: Renee P. Tannenbaum, Pharm.D.

ANI PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Renee P. Tannenbaum, Pharm.D.”): 15,830,187 for, 1,068,993 against, per its Form 8-K filed May 23, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, (i) the eight directors were elected, (ii) the appointment of the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified, (iii) the compensation of the Company's named executive officers, on an advisory basis, was app…”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 6,165,293 for, 335,941 against, 1,630 abstained.

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

Description as filed by funds: Election of Directors: Thomas Haughey

ANI PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Thomas Haughey”): 14,837,619 for, 2,060,363 against, per its Form 8-K filed May 23, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, (i) the eight directors were elected, (ii) the appointment of the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified, (iii) the compensation of the Company's named executive officers, on an advisory basis, was app…”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 5,558,885 for, 942,349 against, 1,630 abstained.

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.

Description as filed by funds: To approve the Amended and Restated 2022 Stock Incentive Plan.

ANI PHARMACEUTICALS INC.’s own tally for this item (“4. Approval o f the Amended 2022 Stock Plan The vote with respect to the approval of the Amended 2022 Stock Plan”): 16,031,866 for, 871,204 against, per its Form 8-K filed May 23, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 92 asset managers below reported 6,397,413 for, 125,081 against, 1,630 abstained.

Showing the 25 largest of 92 asset managers. See all 92 in the interactive database.

Description as filed by funds: To approve the compensation of the Company's named executive officers, on an advisory basis;

ANI PHARMACEUTICALS INC.’s own tally for this item (“3. Approval of the Say-on-Pay Proposal The vote with respect to the approval of the Company's named executive officers, on an advisory basis”): 16,139,473 for, 762,718 against, per its Form 8-K filed May 23, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 86 managers: 6,389,582 for, 111,214 against, 1,630 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 184 managers: 6,955,006 for, 710,397 against, 4,329 abstained, 200 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024;

ANI PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of the Appointment of Independent Registered Public Accounting Firm The vote with respect to the ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accountin”): 18,043,078 for, 56,735 against, per its Form 8-K filed May 23, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 6,501,211 for, 23 against, 1,630 abstained.

Showing the 25 largest of 89 asset managers. See all 89 in the interactive database.